SEC Comment Letter for SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Jun 2, 2021
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: June 2, 2021 · CIK: 0001061027 · Accession: 0000000000-21-006837
AI Filing Summary & Sentiment
File numbers found in text: 333-256647
Letter
United States securities and exchange commission logo June 2, 2021 Ivor Royston, M.D. President and Chief Executive Officer Viracta Therapeutics, Inc. 2533 S Coast Hwy 101, Suite 210 Cardiff, CA 92007 Re:Viracta Therapeutics, Inc. Registration Statement on Form S-3 Filed May 28, 2021 File No. 333-256647 Dear Dr. Royston: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Martin Waters, Esq.
Show Raw Text
United States securities and exchange commission logo
June 2, 2021
Ivor Royston, M.D.
President and Chief Executive Officer
Viracta Therapeutics, Inc.
2533 S Coast Hwy 101, Suite 210
Cardiff, CA 92007
Re:Viracta Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 28, 2021
File No. 333-256647
Dear Dr. Royston:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Martin Waters, Esq.